Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

VERA stock hub

Vera Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

VERAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

2.6B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

VERA

In the news

Latest news · VERA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-71.3

P25 -105.6P50 -46.5P75 -3.1

ROIC-41.1

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All VERA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

167

Groups with data

Currency

USD

Showing 167 of 167 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001831828
Company name	Vera Therapeutics, Inc.
Country	United States
Country code	US
Cusip	92337R101
Employees	249
Employees Change	137%
Employees Change Percent	122.3
Enterprise value	$2.1B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-05-14
Isin	US92337R1014
Last refreshed	2026-05-10
Market cap	$2.6B
Market cap category	Mid-Cap
Price	$36.19
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	VERA
Website	https://veratx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-14.2%
P/B ratio	5.18x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-369M
Net Income Growth Years	0%
Profit Per Employee	$-1.5M
ROA	-38.9
Roa5y	-35.79
ROCE	-66.5
ROE	-71.32
Roe5y	-75.81
ROIC	-41.1

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	60.04%
Cagr3y	69.42%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$621.7M
Cash	$596.8M
Current Assets	$615.8M
Current Liabilities	$45.1M
Debt	$76.9M
Debt Equity	$0.15
Equity	$499.7M
Interest Coverage	-50.91
Liabilities	$122M
Long Term Assets	$5.9M
Long Term Liabilities	$76.9M
Net Cash	$519.9M
Net Cash By Market Cap	$20.01
Net Cash Growth	-2.9%
Net Debt Equity	$-1.04
Tangible Book Value	$499.7M
Tangible Book Value Per Share	$6.99
WACC	9.43

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	13.64
Net Working Capital	$-26.1M
Quick ratio	13.22
Working Capital	$570.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-13.13%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	59.99%
200-day SMA	35.35
3Y total return	386.43%
50-day SMA	39.6
50-day SMA vs 200-day SMA	50over200
All Time High	56.05
All Time High Change	-35.43%
All Time High Date	2025-12-24
All Time Low	5.2
All Time Low Change	595.96%
All Time Low Date	2023-01-06
ATR	2
Beta	0.95
Beta1y	1.19
Beta2y	1.21
Ch YTD	-28.53
High	36.93
High52	56.05
High52 Date	2025-12-24
High52ch	-35.43%
Low	35.75
Low52	18.76
Low52 Date	2025-05-29
Low52ch	92.91%
Ma50ch	-8.61%
Price vs 200-day SMA	2.39%
RSI	40.32
RSI Monthly	53.13
RSI Weekly	45.65
Sharpe ratio	0.86x
Sortino ratio	1.96
Total Return	-13.13%
Tr YTD	-28.53
Tr1m	-9.53%
Tr1w	2.81%
Tr3m	-16.8%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	9
Analyst Count Top	4
Analyst Price Target Top	$87.25
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-1.35
Operating Income	$-383.4M
Price target	$79.22
Price Target Change	$119
Price Target Change Top	$141

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	51,792,104%
Float Percent	72.15%
Shares Insiders	0.92%
Shares Institutions	85.01%
Shares Out	71,782,904
Shares Qo Q	8.92%
Shares Yo Y	13.13%
Short Float	19.06%
Short Ratio	7.35
Short Shares	13.75

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	1,049,025.95x
Bv Per Share	6.99
Ch1m	-9.53
Ch1w	2.81
Ch1y	59.99
Ch3m	-16.8
Ch3y	386.4
Ch6m	49.61
Change	0.86%
Change From Open	1
Close	35.88
Days Gap	-0.14
Depreciation Amortization	500,000
Dollar Volume	28,858,810.8
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$-383.4M
EBITDA	$-382.9M
EPS	$-5.57
F Score	0
Fiscal Year End	December
Founded	2,016
Income Tax	$1,000
Ipr	229
Iprfo	217.2
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	39.37
Ma150ch	-8.07%
Ma20	38.69
Ma20ch	-6.46%
Next Earnings Date	2026-08-04
Open	35.83
Optionable	Yes
Position In Range	37.29
Post Close	36.19
Postmarket Change Percent	0.86
Postmarket Price	$36.5
Price Date	2026-05-08
Ptbv Ratio	5.2
Relative Volume	0.76x
Tr6m	49.61%
Us State	California
Volume	797,425

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does VERA pay a dividend?

Capital-return profile for this ticker.

Performance

VERA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns VERA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+85.0%

Float: +72.2% of shares outstanding

Insider ownership

+0.9%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

VERA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

40.3

Neutral momentum band

Price vs 200-day MA

+2.4%

50/200-day relationship not available

Beta (5Y)

0.95

Moves roughly with the market

Sharpe ratio

0.86

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About VERA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current VERA stock rating?

Vera Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full VERA analysis?

The full report lives at /stocks/VERA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for VERA?

The latest report frames VERA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the VERA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.